Search results for " Major]"

showing 3 items of 3 documents

The Relationship Between Polygenic Risk Scores and Cognition in Schizophrenia

2020

Abstract Background Cognitive impairment is a clinically important feature of schizophrenia. Polygenic risk score (PRS) methods have demonstrated genetic overlap between schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), educational attainment (EA), and IQ, but very few studies have examined associations between these PRS and cognitive phenotypes within schizophrenia cases. Methods We combined genetic and cognitive data in 3034 schizophrenia cases from 11 samples using the general intelligence factor g as the primary measure of cognition. We used linear regression to examine the association between cognition and PRS for EA, IQ, schizophrenia, BD, and MDD. The results wer…

Multifactorial InheritanceBipolar DisorderDatasets as TopicINTELLIGENCEGenome-wide association study0302 clinical medicinegenetics [Schizophrenia]education.field_of_studyHERITABILITYCOMMON VARIANTSCognitionbioinformaticsintelligencepsychiatryABILITYPsychiatry and Mental healthSchizophreniaMajor depressive disorderEducational Statuspsychiatry genomics intelligence bioinformaticsClinical psychologyPopulationgenetics [Psychotic Disorders]behavioral disciplines and activities03 medical and health sciencesmental disordersgenomicsmedicineHumansBipolar disorderddc:610GENOME-WIDE ASSOCIATIONeducationSettore MED/25 - PsichiatriaMETAANALYSISGenetic associationDepressive Disorder MajorENDOPHENOTYPESbusiness.industryMEMORYCONSORTIUMgenetics [Depressive Disorder Major]PERFORMANCEmedicine.disease030227 psychiatryPsychotic Disordersgenetics [Intelligence]EndophenotypeSchizophreniabusiness030217 neurology & neurosurgerygenetics [Bipolar Disorder]Regular ArticlesGenome-Wide Association Study
researchProduct

Genome-wide association data provide further support for an association between 5-HTTLPR and major depressive disorder.

2013

Abstract Background Dysfunctions of serotonergic neurotransmission are supposed to be involved in the pathogenesis of psychiatric disorders such as major depressive disorder (MDD). The concentration of serotonin (5-hydroxytryptamine, 5-HT) in the synaptic cleft is essentially regulated by the 5-HT transporter (5-HTT). A length polymorphism repeat in the 5-HTT promoter region, termed 5-HTTLPR, has been commonly investigated for an association with psychiatric disorders. Methods Genotyping of the 5-HTTLPR is time-consuming and technically challenging. Recently, a two-SNP haplotype was identified that tags the 5-HTTLPR at r 2 =0.775. This allows extraction of 5-HTTLPR genotype information from…

AdultMaleLinkage disequilibriumSynaptic cleftGenotypeSingle-nucleotide polymorphismGenome-wide association studyPolymorphism Single NucleotideGermanygenetics [Haplotypes]mental disordersGenotypegenetics [Serotonin Plasma Membrane Transport Proteins]medicineHumansGenetic Predisposition to Diseaseddc:610GeneticsSerotonin Plasma Membrane Transport ProteinsDepressive Disorder MajorSLC6A4 protein humanHaplotypegenetics [Depressive Disorder Major]Middle Agedmedicine.diseasePsychiatry and Mental healthClinical PsychologyHaplotypes5-HTTLPRCase-Control Studiesgenetics [Polymorphism Single Nucleotide]Major depressive disorderFemalePsychologyClinical psychologyGenome-Wide Association StudyJournal of affective disorders
researchProduct

Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study

2018

<b><i>Background:</i></b> No candidate biomarkers based on cerebrospinal fluid (CSF) have been identified as prognostic factors in patients with major depression treated with electroconvulsive therapy (ECT), yet. <b><i>Method:</i></b> Following different underlying hypotheses, we analysed baseline CSF levels of markers of neurodegeneration (tau proteins, β-amyloids and neurogranin), elements of the innate immune system (interleukin [IL]-6, neopterin, soluble CD14, soluble CD163, migration inhibitory factor and monocyte chemotactic protein 1), endocannabinoids, sphingolipids and Klotho before ECT in patients with depression (<i>n</i&gt…

MaleOncologymedicine.medical_treatmentchemistry.chemical_compound0302 clinical medicineCerebrospinal fluidElectroconvulsive therapyNeurogranincerebrospinal fluid [Sphingolipids]Electroconvulsive TherapyKlothoGlucuronidaseAged 80 and overtherapy [Depressive Disorder Major]NeopterinInterleukinMiddle AgedPsychiatry and Mental healthTreatment OutcomeNeuropsychology and Physiological Psychologycerebrospinal fluid [Biomarkers]cerebrospinal fluid [Glucuronidase]Biomarker (medicine)AntidepressantFemaleAdultmedicine.medical_specialtyklotho proteinYoung Adult03 medical and health sciencesInternal medicinemental disordersmedicineHumansddc:610Klotho ProteinsBiological Psychiatrycerebrospinal fluid [Nerve Degeneration]AgedDepressive Disorder MajorSphingolipidsbusiness.industrycerebrospinal fluid [Depressive Disorder Major]Immunity Innate030227 psychiatrychemistryNerve Degenerationcerebrospinal fluid [Endocannabinoids]businessBiomarkers030217 neurology & neurosurgeryEndocannabinoidsNeuropsychobiology
researchProduct